Cyplasin Announces Commencement of Second Animal Efficacy Study



    CYPL: OTCBB, Frankfurt Exchange WKN:XYIA

    EDMONTON, Jan. 18 /CNW/ - Cyplasin Biomedical Ltd. (CBL), is pleased to
announce the commencement of a second animal efficacy study of its lead
product Cyplasin-SC(TM) for use as a melanoma cancer therapeutic. The second
study will be performed by Aurigon Life Sciences GmbH (Tutzing, Germany) to
reconfirm CBL's previously successful animal efficacy study of Cyplasin-SC for
melanoma and to test a newly formulated Cyplasin-solution that will be even
better tolerated by the mouse organism.
    The second study of Cyplasin-SC will be performed as before where mice
with a suppressed immune system are given human melanoma cells in order to
create melanoma tumours in the mice. These melanoma tumours will then be
allowed to grow to a sufficient size to allow for repeated microinjection of
Cyplasin-SC at or near the tumour site. After a specified period of time the
tumours will then be analysed to determine if the Cyplasin-SC has retarded or
stopped the growth of the tumour.
    "Our first study confirmed a definitive correlation with the amount of
Cyplasin-SC being given versus a reduced tumour size and we have every
confidence this second study will be as successful," stated Professor Petzelt,
CSO of the Company. He further stated "once we have obtained and analysed the
new confirming data we can then plan on how to best move into the animal
toxicology testing phase before IND submission and the resultant initiation of
phase I, experiments involving humans."
    Cyplasin-SC is being developed for use as an anticancer therapeutic drug
for melanoma and skin cancer.

    About Melanoma

    Around 160,000 new cases of new melanoma cases are diagnosed worldwide
each year. Melanoma is more frequently found in Caucasian males and is more
common in Caucasian populations living in sunny climates than in other groups.
Market statistics for skin cancer and melanoma show that melanoma currently
affects more then 2.4 million people worldwide with 62,000 new cases being
reported in the USA every year. Australia has the highest rate of melanoma in
the world among males and has the second highest rate in the world among
females (Australia's Health 2004, AIHW). According to the WHO Report the world
wide incidence has doubled over the past 20 years with about 48,000 melanoma
related deaths occurring worldwide per annum.

    About Cyplasin-SC(TM)

    Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill
certain types of cancer cells while leaving normal non-cancerous cells
untouched. Cyplasin-SC is a protein originally discovered and isolated by
Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The
protein can now be manufactured as a recombinant protein which allows the
company to develop the protein as an anti-cancer therapeutic product. Patents
have been issued to the Company covering the Cyplasin-SC protein.

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Canada with a research
laboratory close to Berlin, Germany, CBL is dedicated to bringing new
anticancer therapeutics to the marketplace. The Company's current goal is to
develop and commercialize the anticancer properties of Cyplasin-SC(TM) against
skin cancer and melanoma. CBL is publicly traded (CYPL: OTCBB).

    Forward-Looking Statements

    This Press release includes and is based, inter alia, on forward-looking
information and statements that are subject to risks and uncertainties that
could cause actual results to differ. Such forward-looking information and
statements are based without limitation, as statements regarding future drug
development activities, anticipated products, or anticipated future revenues,
benefits or advantages, and the future plans and objectives of the Company,
that involve inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, such as market acceptance of new
products and services, changes in governmental regulations, interest rates,
fluctuations in currency exchange rates and such other factors as may be
discussed from time to time that may cause actual results or performance to
differ materially from those currently anticipated in such statements. These
expectations, estimates and projections are generally identifiable by
statements containing words such as "expects", "believes", "estimates" or
similar expressions. Although Cyplasin Biomedical Ltd., believes that its
expectations and the information in this Press release were based upon
reasonable assumptions at the time when they were made, it can give no
assurance that those expectations will be achieved or that the actual results
will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no
representation or warranty, expressed or implied, as to the accuracy,
reliability or completeness of the information in the Press release, and
neither Cyplasin Biomedical nor any of their directors, officers or employees
will have any liability to you or any other persons resulting from your use of
the information in the Press release. The OTCBB Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of this news
release.





For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd., www.cyplasin.com, Tel 001-780-469-2975, Fax 001-780-699-7933,
glikes@cyplasin.com; Professor Christian Petzelt (CSO), Cyplasin Biomedical
Ltd., www.cyplasin.com, Tel 0049-30-95992761, cpetzelt@cyplasin.com

Organization Profile

CYPLASIN BIOMEDICAL LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890